Med-Spa and Aesthetics: Market Evolution

A Market Growing Faster Than Its Own Numbers Agree On

The American Med Spa Association's own statistics page, checked directly, confirms the US medical spa industry generates more than $17 billion a year in revenue and continues to add more than $1 billion a year in growth. AmSpa's fuller claim of a $21.4 billion 2026 estimate and a 14.2% compound annual growth rate since 2020 lives behind its paywalled full report and could not be independently re-derived, so it belongs to the association's own messaging rather than to confirmed public data. Independent commercial research firms tell a broadly similar growth story but disagree sharply on scale: Grand View Research and three comparable firms put the 2026 market anywhere from the low $20 billions to nearly $28 billion, rising to somewhere between $78 billion and $105 billion by 2033 to 2035, a three-to-fourfold spread across firms that are ostensibly measuring the same category. That spread is itself informative. It means no shared definition of what counts as a med spa, and no common measurement method, exists across the vendors who publish these numbers, so any single market-size figure quoted in this category should be read as directional, not precise.

What is easier to trust is the shape of the growth. AmSpa's own annual survey found the number of operating med spas in the US rose from 8,899 in 2022 to 10,488 in 2023, and the repeat-patient rate climbed from 65% to 73% between 2022 and 2024, both signs of a category adding new locations and deepening relationships with the patients it already has. Layered on top of that, 2026 is being described by AmSpa and by M&A advisory commentary as on pace for a record year of private-equity-backed consolidation, with adjusted EBITDA multiples reported roughly in the 6x to 13x range depending on scale and management-services-organization structure. That is a forward-looking industry forecast, not a settled historical fact, and it should be read that way.

A three-to-fourfold spread in market-size estimates across four commercial research firms is itself evidence that no one has agreed on how to measure this category.

What's Actually Being Bought: Procedure Volume and Repeat Business

Behind the market-size uncertainty sits firmer ground: what people are actually buying. The American Society of Plastic Surgeons, whose procedural data is peer-reviewed and independently cross-published, counted 28,243,407 minimally invasive procedures performed in the US in 2024, 91.5% of total plastic-surgery-adjacent procedural volume, up 3% year over year. Neuromodulators, the Botox-family category, remained the single most-performed treatment and grew 4% year over year, while hyaluronic-acid fillers grew 1%. The five highest-volume minimally invasive procedures together accounted for 83.6% of that category's volume, meaning most of the demand in this market concentrates in a small set of well-understood, repeatable treatments rather than spreading thin across many niche procedures.

Read alongside AmSpa's repeat-patient figures, a consistent picture emerges: this is a category built substantially on retention, not one-time acquisition. Patients who try neuromodulators or fillers tend to come back, and the highest-volume treatments are also the ones most patients already have some familiarity with before they walk in the door. That has a direct implication for discovery: a provider competing for a new patient's first visit is competing not against an unfamiliar category but against an established habit the patient already has somewhere, which raises the bar for what makes a first-time visitor choose a new provider over their existing one.

Where Patients Look First: The Local-Search-to-Video Handoff

BrightLocal's 2025 Local Consumer Review Survey, a long-running annual industry survey rather than a one-off marketing claim, found Google remains the dominant platform consumers check before choosing a local business, at 83%, followed by local news sites at 48%, Yelp at 44%, Facebook at 40%, YouTube at 34%, and TikTok at 20%. The same survey found consumers typically check at least two review sites before deciding, and that overall trust in online reviews sits below its 2016 to 2017 peak of 84%. For an aesthetic-services provider this means a strong Google Business Profile and review footprint is necessary but no longer sufficient on its own, because most prospective patients are cross-checking at least one other surface before they call.

Short video has become one of those surfaces in a way that is specific to this category. A 2024 survey of TikTok skincare-content consumers, published in an open-access peer-reviewed journal though with the methodological caveats of a single, non-nationally-representative sample, found 61.6% agreed the platform's skincare content shapes their beauty perceptions, and about 66% said they trust recommendations from skincare influencers on the platform. That trust sits uneasily next to a 2022 content-quality audit published in the Journal of Aesthetic Nursing, which found 83% of videos discussing dermatological treatments on the platform were produced by creators with no medical credential, and only about 15% of those videos mentioned any potential adverse effect of the treatment shown. Patients are forming opinions about treatments, in large numbers, from a content pool that mostly is not made by clinicians and mostly does not mention risk.

Most of the video content shaping how patients think about aesthetic treatments is made by people with no medical credential, and only about 15% of it mentions any adverse effect.

The AI Layer: Convenient, Not Yet Trusted

The newest discovery surface is also the least settled, and the evidence here is unusually strong for how early the category is: a nationally representative Pew Research Center survey of 5,111 US adults, fielded October 20 to 26, 2025 and published in April 2026, found only 22% of US adults use AI chatbots for health information at least sometimes, rising to 32% among 18-to-29-year-olds, against 85% who still rely on a healthcare provider. Among those who do use a chatbot for health information, only 18% rate what it tells them as highly accurate, compared with 65% who say the same about information from a provider, while 48% call the chatbot experience highly convenient. That is a wide, well-documented gap between how often people reach for these tools and how much they trust what comes back, and it was independently confirmed by fetching Pew's own page directly rather than taken on secondhand report.

What the AI-answer layer actually shows about any specific provider is even less settled. A vendor-run six-week tracking study of URLs cited in generative-engine answers found only 119 of 1,127 unique cited URLs, about 10.6%, persisted across all three measurement waves spaced roughly four weeks apart, suggesting whatever a chatbot cites about a market today is likely to be different a month from now. That study was methodologically only partially disclosed and has not been independently replicated, so it should be read as directional evidence that this layer is volatile, not as a precise churn rate. A separate, frequently repeated claim that AI Overviews now cover roughly half of all Google searches, with an outsized 88% share in healthcare, could not be reconciled with the source it was attributed to on direct inspection and has been excluded from this study rather than included with a caveat. No independent census of how often aesthetic-services queries specifically surface a given provider in a generative-engine answer currently exists. That absence, not a number, is the honest state of this channel today.

Only 18% of people who use an AI chatbot for health information call it highly accurate, versus 65% who say the same about a healthcare provider, yet nearly a quarter of US adults already reach for the chatbot.

The Credence-Good Problem: Why Patients Can't Pre-Verify Skill

Aesthetic services sit in a category economists call a credence good: the patient cannot assess the provider's actual skill, the product's provenance, or the real safety risk before they buy, and often cannot fully assess it afterward either. That would matter less if the ownership and licensing structure behind a med spa were easy for a patient to verify from the outside, but the evidence suggests it usually is not. Corporate-practice-of-medicine doctrine bars non-physician ownership of the clinical entity in strict-CPOM states, which forces a split structure between a professional corporation and a management-services organization for non-physician investors. Several states reportedly intensified enforcement against passive or non-compliant med-spa ownership arrangements through 2025 and 2026, according to legal-industry sources, though this rests on legal-blog analysis rather than a directly retrieved state-board dataset, and a specific claim that California expanded qualifying nurse-practitioner ownership eligibility starting January 2026 could not be verified against primary statutory text. None of this structure, verified or not, is something a prospective patient can see by looking at a med spa's Google listing, Instagram feed, or TikTok presence.

That is the structural mismatch at the center of this study: the channels where patients are increasingly forming their first impression, Google's local pack, short video, review sites, and now AI chat, carry almost none of the credential information that would let a patient tell a board-certified, properly supervised practice from one operating in a legal or clinical gray zone. The gap is not hypothetical. It is the same gap that shows up, in concrete and sometimes fatal form, in the enforcement pattern documented below.

The Enforcement Wave: When the Trust Gap Becomes a Prosecution

Independent news investigations across multiple states in 2026 document a recurring pattern that gives the credence-good problem a human face. Reported cases include a fatal NAD+ IV injection in the Bronx in July 2026, a Houston lip-filler injection performed without a medical license that caused an infection in early to mid-2026, a Texas med-spa owner charged with murder after a rapid IV cocktail caused fatal cardiac arrest in the spring of 2026, and a Sun-Sentinel investigative series describing Florida med spas operating with little government oversight and, in some cases, misrepresented physician supervision. These are separate incidents reported by separate outlets across separate states, converging on the same underlying pattern rather than a single source making a single claim, which is why this finding holds up at an established tier even though individual article pages returned fetch errors during verification and were not re-read line by line in this pass.

This pattern sits directly beside the record-consolidation, growing-repeat-rate story from earlier in this study, and both are true at once. A category can be growing, professionalizing at its upper end, and still have a persistent lower tail of unlicensed or undersupervised operators exploiting exactly the discovery channels, low-verification, high-trust social and local platforms, that this study has described. For a legitimate, properly credentialed provider, that is not only a public-safety concern to be aware of. It is also a competitive opening: on channels where most content carries no visible credential signal at all, being the practice that visibly and verifiably does is a real point of difference, not a marketing flourish.

A category can be growing and professionalizing at its upper end while a persistent lower tail exploits the exact same low-verification discovery channels.

The Reviews Rulebook: What the FTC Now Requires

Reviews are one of the few places in this discovery mix where the rules are settled rather than emerging. The FTC's final rule banning fake and paid consumer reviews and testimonials was announced August 14, 2024 and took effect October 21, 2024, applying broadly across industries including medical spas and cosmetic services. The rule carries civil penalties of up to $51,744 per violation and explicitly bars insider reviews posted without disclosure, paid reviews presented as organic, and fabricated or synthesized testimonials, whether generated by a person or a tool. Direct access to the FTC's own page was blocked by bot detection during verification for this study, but the rule, its effective date, and its penalty figure are well-documented public regulatory facts corroborated by multiple independent legal summaries, which is why this finding stands at an established tier.

For a category already under scrutiny for thin licensing oversight, this rule raises the stakes on the review and testimonial side specifically. A med spa's review profile is one of the few credibility signals a prospective patient actually has direct access to before booking, given how little of the credential and supervision information described earlier makes it onto public-facing channels. Treating that review profile as a compliance surface, not just a marketing asset, protects against real financial exposure and also happens to be the honest, sustainable version of the same trust-building work this study argues the category needs more of.

Where This Leaves an Aesthetic-Services Provider

Put together, the evidence supports a specific and fairly narrow claim rather than a sweeping one. The market is real and growing by every measure available, even where the exact size is contested. Demand concentrates in a small set of well-understood, repeatable procedures with high repeat-patient rates. Discovery has moved decisively toward Google, short video, and review platforms, with an AI-answer layer that patients are starting to use but do not yet trust the way they trust a provider directly, and that layer itself is measurably unstable from one month to the next. None of the surfaces patients actually use to choose a provider currently carry much, if any, verifiable credential information, and 2026's enforcement pattern shows what that absence can cost when it goes unaddressed.

The opening this creates is not a guarantee of outcomes, and nothing in this evidence supports promising one. It is that credential-forward, honestly reviewed, locally and AI-visible positioning is currently underused relative to how much patients are relying on exactly those surfaces to decide. Knowing where a specific local market's attention actually sits today, across Google, video, review platforms, and the still-forming AI-answer layer, is the starting point for deciding where that kind of positioning would actually be seen. That is what a Visibility Corpus reading of a market is built to show.